Using RCC cell lines, we have revealed that inhibition of GSK-3 results in decreased expression of NF-kB target genes Bcl-2 and XIAP leading to a subsequent increase in RCC apoptosis and the anti-tumor effect of sorafenib, TKI available for treatment of mRCC in clinical practice [20, 22]. The gene discussed is BCL2; the disease is renal cell carcinoma.